Table 3.
Antiproliferative properties of potent hydroxamates against cancer cell lines displaying apoptosis resistance and representing cancers with dismal prognoses
| compound | GI50 in vitro values (μM)a | |||
|---|---|---|---|---|
|
| ||||
| glioma | lung carcinoma | |||
|
| ||||
| Hs683 | U87 | T98G | A549 | |
| 3aafa | 8.9 ± 0.4 | 9.5 ± 0.3 | 36.4 ± 1.9 | 2.8 ± 0.4 |
| 3aafe | 6.1 ± 1.0 | 5.0 ± 0.5 | 8.8 ± 0.5 | 3.3 ± 0.6 |
| 3aafk | 4.7 ± 1.0 | 6.7 ± 1.5 | 7.5 ± 0.8 | 2.9 ± 0.6 |
| 3cafa | 10.8 ± 0.5 | 6.7 ± 0.3 | 12.3 ± 0.8 | 5.7 ± 0.5 |
| 3eafa | 11.2 ± 0.9 | 9.1 ± 0.3 | 10.6 ± 0.4 | 5.8 ± 0.8 |
| 3aafp | 5.1 ± 0.5 | 21.3 ± 1.6 | 1.9 ± 0.2 | 1.5 ± 0.3 |
a
Concentration required to reduce the viability of cells by 50% after a 48 h treatment with the indicated compounds relative to a DMSO control ± SD from two independent experiments, each performed in 4 replicates, as determined by the MTT assay.